Bioxytran (BIXT) Gross Margin (2010 - 2018)

Bioxytran (BIXT) posted Gross Margin of 60.04% for Q2 2018, up 513.63% sequentially from 14.52% in Q1 2018, and up 918.0% YoY from 5.9% in Q2 2017.

Bioxytran (BIXT) Gross Margin (2010 - 2018) Analysis & Trends

Bioxytran has reported Gross Margin for 9 years, with the latest figure at 60.04% in Q2 2018.

Quarterly Gross Margin rose 918.0% year-over-year to 60.04% in Q2 2018, while the trailing twelve-month figure through Jun 2018 was 47.11% (down 744.0% YoY) and the FY2017 annual result came in at 45.58%, down 1535.0% from the prior year.
Gross Margin rose to 60.04% in Q2 2018 per BIXT's latest filing, from 14.52% in the prior quarter.
Over five years, Gross Margin peaked at 641.87% in Q4 2014 and troughed at 83.88% in Q1 2017.
A 5-year average of 71.8% and a median of 60.72% in 2016 frame the typical range for Gross Margin.
The sharpest annual moves came in 2014 and 2015: Gross Margin surged 59526 bps in 2014, then sank 64164 bps in 2015.
Over 5 years, Gross Margin stood at 641.87% in 2014, then slumped by 100 bps to 0.23% in 2015, then surged by 26376 bps to 61.39% in 2016, then plunged by 133 bps to 20.49% in 2017, then surged by 393 bps to 60.04% in 2018.
According to Business Quant data, Gross Margin over the past three periods registered 60.04%, 14.52%, and 20.49% for Q2 2018, Q1 2018, and Q4 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	91.59%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	90.43%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	63.27%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Bioxytran	2.52 Mn	2.27 Mn	-	-

Download Data